Clinical Effect of Two Pharmacokinetics Model of Propofol
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Actually, Schnider and Cortinez models represent pharmacokinetics models of propofol more
complete published until now. Schnider was derived from 24 healhty people, and including
other covariates in addition to weight, such as age, height and lean body mass though.
Schnider model should not be used in obese patients. CortÃnez model was derived from 20 obese
patients. The differences between both models has been founded at the initial drug
distribution, that means V1 and the constant Ke0 ( pharmacokinetics factors that define the
plasma-effect equilibration time). We believe that Cortinez model also could be used in No
OBESE patients because is an allometric model, and one way to evaluate and to compare both
pharmacokinetics models is studying the temporary course of the effect.
The main objective of our study is to evaluate BIS and Cardiac Output values during
propofol-induced sedation using Schnider and Cortinez models in Target Controlled infusion in
non obese healthy volunteer.